Vienna, 13.12.2023. At the end of November 2023, AOP Orphan Pharmaceuticals GmbH (AOP Health), an Austrian pharmaceutical company based in Vienna, received authorization from the Canadian Health Authority (Health Canada) for its ultra-short-acting, cardioselective β1-blocker Landiolol. The drug is used in intensive care to treat atrial fibrillation and atrial flutter (supraventricular tachycardia) and non-compensatory sinus tachycardia, hence when the heartbeat accelerates acutely without an identifiable cause. The authorization allows a certain group of intensive care patients access to an additional therapy option. In addition, it opens the door to the North American market for AOP Health.
Landiolol, which is already authorized in the EU, has been repeatedly presented to the Canadian medical community at international medical congresses. In Canada, Landiolol will only be available in hospitals.